logo-loader
HealthPharma & Biotech
Motif Bio PLC

Motif Bio teams up with German university to see if iclaprim can help patients with rare eye disease

Researchers at the Otto-von-Guericke University Magdeburg are to carry out a series of lab tests to evaluate iclaprim as a possible treatment for toxoplasma chorioretinitis

eye
An orphan disease is a condition that affects fewer than 200,000 people around the world

Motif Bio PLC (LON:MTFB) is to explore the possibility of using its iclaprim next-generation antibiotic to treat people with a rare blindness-causing disease called toxoplasma chorioretinitis.

AIM-quoted Motif has tested iclparim in patients with acute bacterial skin and skin structure infections (ABSSSI), for which it is now looking to get regulatory approval.

READ: Motif bosses meet with FDA

But the company has today signed an agreement with the Otto-von-Guericke University Magdeburg in Germany which is to carry out a series of lab tests to see if iclaprim can help people affected by toxoplasma chorioretinitis.

The orphan disease that is a type of ocular toxoplasmosis – a parasitic disease that may result in severe life-threatening infections and/or blindness.

The work will be carried out by professor Ildiko Rita Dunay, a director at the university’s Institute of Inflammation and Neurodegeneration.

“We are very pleased to work with Dr Dunay, who is an expert in the area of toxoplasmosis. In vitro data indicate that iclaprim has activity against toxoplasma,” said chief medical officer David Huang.

“The data generated from Dr Dunay's lab will be important in understanding whether iclaprim can play a role in this potentially devastating, progressive and recurring necrotizing retinitis, including vision-threatening complications.”

Quick facts: Motif Bio PLC

Price: £0.02

Market: AIM
Market Cap: £8.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018

2 min read